We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New Corona Mass Test up to 100 Times More Sensitive than Rapid Antigen Tests

By LabMedica International staff writers
Posted on 01 Jul 2021
A new corona test developed at the University Hospital Bonn can analyze a large number of swabs simultaneously using sequencing technology and has a similarly high sensitivity as the common qPCR test.

The innovative corona test "LAMP-Seq", which has been developed at the University Hospital Bonn (Bonn, Germany) offers the possibility to test many people regularly for the SARS-CoV-2 virus. More...
It offers great potential, especially for systematic testing in daycare centers, schools or companies. In this way, infections can be detected at an early stage and corresponding chains of infection can be interrupted quickly. The LAMP-Seq method detects not only corona infections with the original SARS-CoV-2 virus, but also the novel variants of concern alpha to delta.

For the "LAMP-Seq" test, the Bonn scientists have adapted the already established LAMP method ("Loop-mediated Isothermal Amplification" - propagation of the viral genome at a constant temperature) and made it compatible with sequencing machines used for biomedical research. As a result, many samples can be analyzed simultaneously in a high-throughput procedure. Before thousands of samples are analyzed together in a sequencing run, each individual sample is linked to a molecular barcode. This barcode ensures that each sample can be assigned without doubt, even after thousands of samples have been pooled. This technology significantly reduces the cost per test in comparison to the qPCR test and makes the "LAMP-Seq" procedure a scalable corona mass test.

Even smaller models of the sequencing machines used are capable of analyzing around 10,000 samples in a single run (duration: around 10 to 12 hours). This virtually eliminates laboratory capacity as a limiting factor in testing. In several large studies (including school and employee testing) with a total of around 20,000 tests, the Bonn scientists have extensively tested, optimized and successfully validated the entire upstream and downstream logistics, from sample collection by throat swabs to fully digital feedback of the test results.

While the Bonn scientists have currently focused their innovative method entirely on SARS-CoV-2 testing, "LAMP-Seq" can also be used in the future for differential diagnostics in testing for other viruses such as influenza A and can also be quickly adapted to other viruses. The scientists are currently working on CE certification in order to make the "LAMP-Seq" test available internationally in the near future. Until this approval is obtained, the technically and scientifically fully validated "LAMP-Seq" method will continue to be used for pilot testing.

"Our corona test LAMP-Seq can detect about 100 times lower amounts of virus than current rapid antigen tests and is almost as sensitive and specific as the common qPCR test" said Prof. Dr. Jonathan Schmid-Burgk from the Institute of Clinical Chemistry and Clinical Pharmacology of the UKB. "Added to this is the high scalability of the test. By using sequencing machines, thousands of samples can be analyzed simultaneously."

"Retesting of the entire pool in case of a positive test result is therefore no longer necessary," said Dr. Kerstin Ludwig, Emmy-Noether group leader at the Institute of Human Genetics. "With its high throughput and sensitivity, the "LAMP-Seq" test can make a significant contribution to the screening of undetected infections. Especially in schools or companies, where many people regularly meet, the corona test is ideal to systematically and preventively monitor the occurrence of infections."

Related Links:
University Hospital Bonn


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: Beginning in 2027, Quest will provide access to the Onclarity Self-Collection Kit through clinician, health plan, and consumer-initiated testing channels, along with its patient service center network.

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection

Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.